When Evrofarma SA (ATSE:EVROF) announced its most recent earnings (30 June 2017), I did two things: looked at its past earnings track record, then look at what is happening in the industry. Understanding how Evrofarma performed requires a benchmark rather than trying to assess a standalone number at one point in time. Below is a quick commentary on how I see EVROF has performed. Check out our latest analysis for Evrofarma
How Well Did EVROF Perform?
I like to use the ‘latest twelve-month’ data, which annualizes the latest 6-month earnings release, or some times, the latest annual report is already the most recent financial data. This method enables me to assess various companies on a more comparable basis, using the latest information. For Evrofarma, its most recent bottom-line (trailing twelve month) is €463.00K, which, in comparison to the prior year’s figure, has moved up by 10.50%. Since these figures may be somewhat myopic, I’ve calculated an annualized five-year value for Evrofarma’s earnings, which stands at -€841.62K This suggests that, generally, Evrofarma has been able to increasingly improve its profits over the last few years as well.
What’s the driver of this growth? Let’s take a look at whether it is solely attributable to an industry uplift, or if Evrofarma has experienced some company-specific growth. Over the past few years, Evrofarma expanded its bottom line faster than revenue by efficiently controlling its costs. This resulted in a margin expansion and profitability over time. Eyeballing growth from a sector-level, the GR food industry has been amplifying growth, more than doubling average earnings over the past year, and a less exciting 6.85% over the last five years. This means that whatever uplift the industry is profiting from, Evrofarma has not been able to leverage it as much as its industry peers.
What does this mean?
Evrofarma’s track record can be a valuable insight into its earnings performance, but it certainly doesn’t tell the whole story. Positive growth and profitability are what investors like to see in a company’s track record, but how do we properly assess sustainability? I recommend you continue to research Evrofarma to get a more holistic view of the stock by looking at:
-
1. Financial Health: Is EVROF’s operations financially sustainable? Balance sheets can be hard to analyze, which is why we’ve done it for you. Check out our financial health checks here.
-
2. Valuation: What is EVROF worth today? Is the stock undervalued, even when its growth outlook is factored into its intrinsic value? The intrinsic value infographic in our free research report helps visualize whether EVROF is currently mispriced by the market.
-
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
NB: Figures in this article are calculated using data from the trailing twelve months from 30 June 2017. This may not be consistent with full year annual report figures.
To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.
The author is an independent contributor and at the time of publication had no position in the stocks mentioned.